| Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation (NCT05308446) | National Cancer Institute (NCI) | 2022-07-19 |
| A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer (NCT05130060) | Mayo Clinic | 2022-01-10 |
| BRIANSTORM - Early Identification of Patients With Brain Metastases (NCT05185557) | Aarhus University Hospital | 2021-08-16 |
| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer (NCT04616183) | M.D. Anderson Cancer Center | 2020-12-02 |
| SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial (NCT04599140) | M.D. Anderson Cancer Center | 2020-10-14 |
| Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer (NCT04044430) | University of California, San Francisco | 2020-08-31 |
| Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer (NCT04362839) | City of Hope Medical Center | 2020-05-27 |
| Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer (NCT03992456) | Academic and Community Cancer Research United | 2020-04-24 |
| Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial (NCT03765736) | Academic and Community Cancer Research United | 2020-04-20 |
| TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study (NCT04109924) | Roswell Park Cancer Institute | 2019-12-27 |
| Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer (NCT03592641) | National Cancer Institute (NCI) | 2019-07-25 |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer (NCT04017650) | M.D. Anderson Cancer Center | 2019-06-14 |
| Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer (NCT03300544) | National Cancer Institute (NCI) | 2019-05-14 |
| Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer (NCT02874885) | M.D. Anderson Cancer Center | 2013-09-05 |